Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8060600 | 0.82 | TSHR (0.56) | TSHRSMN1; SMN2MAPTKMT2AHPGD | |
| SCHEMBL252121 | 0.82 | TSHR (0.56) | TSHRSMN1; SMN2MAPTKMT2AHPGD | |
| SCHEMBL5850172 | 0.78 | — | — | |
| SCHEMBL5138597 | 0.77 | SMN1; SMN2 (0.52) | TSHRSMN1; SMN2MAPTKMT2AHPGD | |
| SCHEMBL3795914 | 0.75 | — | — | |
| SCHEMBL17859667 | 0.75 | SMN1; SMN2 (0.50) | TSHRSMN1; SMN2MAPTKMT2AHPGD | |
| SCHEMBL17859666 | 0.75 | SMN1; SMN2 (0.50) | TSHRSMN1; SMN2MAPTKMT2AHPGD | |
| SCHEMBL11830302 | 0.73 | — | — | |
| SCHEMBL9706909 | 0.73 | — | — | |
| SCHEMBL2362410 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| EP-2948450-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-1542718-B1 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION | XIE DONG (US) | 2015-11-11 | — | — | EP | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20140187476-A1 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION | BAOBAB PHARMACEUTICALS LIMITED (HK) | 2014-07-03 | — | — | US | disclosed |
| US-8470527-B2 | Method of inhibiting HIV-1 replication by administering modified GP41 C34 peptide derivatives with enhanced pharmacological properties | Frontier Biotechnologies, Co., Ltd. (CN) | 2013-06-25 | — | — | US | disclosed |
| US-20120065369-A1 | LONG LASTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION | QURAISHI OMAR (CA) | 2012-03-15 | — | — | US | disclosed |
| US-20110166061-A1 | LONG LASTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION | CONJUCHEM BIOTECHNOLOGIES, INC. (CA) | 2011-07-07 | — | — | US | disclosed |
| US-20110028746-A1 | METHOD FOR THE DECARBOXYLATIVE HYDROFORMYLATION OF ALPHA, BETA- UNSATURATED CARBOXYLIC ACIDS | BASF SE (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20050065075-A1 | Long lasting fusion peptide inhibitors for hiv infection | CONJUCHEM, LLC | 2005-03-24 | — | — | US | disclosed |
| WO-2004029201-A2 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION | FRONTIER BIOTECHNOLOGIES CO., LTD (CN) | 2004-04-08 | — | — | WO | disclosed |
| EP-1390399-A2 | LONG LASTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION | Conjuchem, Inc. (CA) | 2004-02-25 | — | — | EP | disclosed |
| WO-2004011498-A2 | LONG LASTING NATRIURETIC PEPTIDE DERIVATIVES | CONJUCHEM INC. (CA) | 2004-02-05 | — | — | WO | disclosed |
| EP-1360202-A2 | LONG LASTING GLUCAGON-LIKE PEPTIDE 2 (GLP-2) FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS | ConjuChem, Inc. (CA) | 2003-11-12 | — | — | EP | disclosed |
| EP-1355941-A2 | LONG LASTING GROWTH HORMONE RELEASING FACTOR DERIVATIVES | ConjuChem, Inc. (CA) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002096935-A2 | LONG LASTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION | CONJUCHEM, INC. (CA) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002066511-A2 | LONG LASTING GLUCAGON-LIKE PEPTIDE 2 (GLP-2) FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS | CONJUCHEM INC. (CA) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002062844-A2 | LONG LASTING GROWTH HORMONE RELEASING FACTOR DERIVATIVES | CONJUCHEM INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| US-4808713-A | Anthypertensive pyridazo [1,2-a][1,2]diazepines | HOFFMAN-LA ROCHE INC. (US) | 1989-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | TSHR 1086/4885SMN1; SMN2 1142/4885MAPT 2507/4885 |
| US-20120065369-A1 | LONG LASTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION | VIP, HM13, MAVS | TSHR 3276/4885SMN1; SMN2 1197/4885MAPT 2728/4885 |
| US-20050065075-A1 | Long lasting fusion peptide inhibitors for hiv infection | VIP, HM13, FURIN | TSHR 2862/4885SMN1; SMN2 1739/4885MAPT 3422/4885 |
| US-20140187476-A1 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION | VIP, HM13, BST2 | TSHR 4100/4885SMN1; SMN2 4076/4885MAPT 1838/4885 |
| US-20110028746-A1 | METHOD FOR THE DECARBOXYLATIVE HYDROFORMYLATION OF ALPHA, BETA- UNSATURATED CARBOXYLIC ACIDS | PCCA, CBR3, CBR1 | TSHR 2153/4885SMN1; SMN2 1721/4885MAPT 4847/4885 |
| US-20110166061-A1 | LONG LASTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION | VIP, HM13, FURIN | TSHR 2891/4885SMN1; SMN2 1937/4885MAPT 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.